ABCB1 (P-glycoprotein / CD243) Drug Discovery Landscape & Assay Solutions
- By admin
- 16 Aug 2026
- Comments
Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Multi-Drug Resistance (MDR) and ADME Profiling Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ABCB1 (P-glycoprotein) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery (Optimal for Complex Membrane Protein) | ABCB1 Lentivirus Premade Particles Full-length ORF for stable cell lines. Essential for efflux assays. |
View ABCB1 Products |
| Antigen | ABCB1 Extracellular Loop / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View ABCB1 Products |
| Benchmark Ab | Anti-ABCB1 Benchmark Antibody Recombinant positive control for Flow Cytometry. |
View ABCB1 Products |
| Validator | ABCB1 siRNA Set For knockdown verification in MDR cell lines. |
View ABCB1 Products |
| Related Target A | ABCG2 (BCRP) Synergistic multidrug efflux transporter often co-expressed. |
View ABCG2 Products |
| Related Target B | ABCC1 (MRP1) Key pathway partner in cancer drug resistance. |
View ABCC1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Multi-Pass Structure | Premade Lentivirus for robust, native-conformation stable cell line generation. |
| Species Cross-Reactivity (ADME Tox) | Human/Mouse/Cyno ortholog sequence-verified constructs available. |
| Lack of Validated Controls | High-purity Benchmark Antibodies included for robust assay baseline. |
| False Positives in Efflux Assays | Validated siRNA included for specificity and baseline knockdown checks. |
Live ABCB1 (P-gp) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The role of ABCB1 (P-glycoprotein / CD243) is dual-faceted: it is a primary barrier in neuropharmacology (Blood-Brain Barrier efflux) and a major driver of Multi-Drug Resistance (MDR) in oncology. While early-generation ABCB1 inhibitors faced toxicity challenges, the current R&D wave focuses on rational drug design to evade P-gp efflux, highly specific localized inhibitors, and nanocarrier drug delivery systems. Comprehensive in vitro ADME screening remains the highest demand area for ABCB1 models.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Inhibitors) | Novartis, Pfizer, Roche | Refractory Solid Tumors, Leukemia | Efflux Assay (Need stable Lentivirus cell lines) |
| CNS Therapeutics | Biogen, Eli Lilly | Neurodegeneration (ADME/BBB) | Substrate Profiling (Need native conformation models) |
| Targeted Delivery / Nanoparticles | Various Biotechs | Chemo-resistance Bypass | Internalization Assay (Need functional membrane expression) |